Insider buying · SEC Form 4

Insider Buying — Jul 7, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

7insider buys
$8.78Mbought in total
5companies
2by CEOs, CFOs and other chiefs
HDSNlargest: $4.48M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
HDSNHudson Technologies, Inc.Hartree Partners, LP10% Owner$4.48M764,202$5.86AddedJul 6, 2026
3-day cluster buy June 30–July 2 at $5.68–$5.97/share. Now $6.02 (+2.7% vs avg $5.86). Hartree is a commodity trading firm; HDSN is a refrigerant gas recycler. July 2 tranche ($1.62M) filed July 6 per holiday-extension deadline. Hartree now holds ~11.8% of HDSN.
RHRHCarlos AlberiniDirector$1.83M11,388$160.85AddedJul 1, 2026
Purchased June 29, 2026 via Carlos & Andrea Alberini Trust at weighted avg $160.73/share (prices ranged $158.50–$161.34). Now $169.00 (+5.1% since buy). Director open-market purchase at near-term lows.
NVCTNuvectis Pharma, Inc.Marlio Charles Mosseri10% Owner$916K50,000$18.32AddedJul 1, 2026
Purchased June 30 via Emerald Hill Ventures SA at $18.32/share (range $18.29–$18.32). Now $19.63 (+7.2% since buy). Simultaneous cluster: CEO Ron Bentsur also bought 12,500 shares at $20.00 ($250K). Oncology biotech with recent public offering.
BOLDBoundless Bio, Inc.Kevin Tang / Tang Capital Management10% Owner$715K286,333$2.50AddedJun 29, 2026
First tranche: June 25–29 at ~$2.50 avg. Filed June 29. Second tranche (July 2 filing): 107,463 additional shares at ~$2.50 ($268,880), filed July 6. Combined BOLD purchases ~$983K. Stock at $2.50 (flat). Form 425 on file suggests a potential merger or strategic combination.
FTHFaeth Therapeutics, Inc.Brian C. StephensonCFO$326K13,634$23.92AddedJul 6, 2026
Purchased June 29–July 1 at $22.95–$24.98/share (avg $23.92). Now $24.49 (+2.4% since avg). CFO open-market buy is high-conviction signal. Filing deadline (July 1 last transaction + holiday) landed July 6.
BOLDBoundless Bio, Inc.Kevin Tang / Tang Capital Management10% Owner$269K107,463$2.50AddedJul 6, 2026
Second Tang Capital tranche: June 30–July 2 at ~$2.50 avg. Filed July 6 (holiday-adjusted deadline for July 2 transactions). Stock at $2.50 (flat vs buy). See first BOLD entry for merger context.
NVCTNuvectis Pharma, Inc.Ron BentsurCEO$250K12,500$20.00AddedJul 1, 2026
CEO bought June 30 at exactly $20.00/share — likely tied to concurrent public offering at $20. Now $19.63 (-1.9%, slightly underwater). Part of NVCT cluster buy week alongside 10% owner Mosseri ($916K buy same day).

AIThe day in insider buying

SEC Form 4 Insider Scan — July 7, 2026

Scanned the last 24–48 hours of EDGAR Form 4 filings (Independence Day holiday weekend compressed the filing window: July 2 transactions were due July 6, the first business day after the July 3–5 holiday). 6 qualifying buys (≥ $250K, transaction type P) totalling ~$7.56M.

Context: EDGAR was backlogged from the July 4 holiday weekend. The effective filing window covered transactions from June 29–July 2, 2026, with filings due on or by July 6 (Monday). Direct EDGAR API access was blocked by proxy; data sourced from SEC-aggregator feeds (Investing.com, Quiver Quantitative, StockTitan, Benzinga).

Headline Filings

  • HDSN — Hartree Partners LP (10% Owner) bought 764,202 shares ≈ $4.48M at $5.86 avg (June 30–July 2); now $6.02 (++2.7% since buy). 3-day cluster buy; Hartree is a commodity trading/energy firm accumulating in a refrigerant gas recycler. (filing)
  • RH — Director Carlos Alberini (via Carlos & Andrea Alberini Trust) bought 11,388 shares ≈ $1.83M at $160.73 avg (June 29); now $169.00 (+5.1% since buy). Director buying at lows in a high-end home furnishing retailer; stock has recovered above the purchase price. (filing)
  • NVCT — 10% Owner Marlio Charles Mosseri (via Emerald Hill Ventures SA) bought 50,000 shares ≈ $916K at $18.32 (June 30); now $19.63 (+7.2% since buy). Cluster buy alongside CEO Ron Bentsur who also purchased $250K at $20.00/share. Nuvectis Pharma is a small oncology biotech. (filing)
  • BOLD — 10% Owner Tang Capital Management bought a combined $983,648 across two Form 4s: 286,333 shares at ~$2.50 avg (June 25–29, filed June 29) and 107,463 shares at ~$2.50 (June 30–July 2, filed July 6). Stock now at $2.50 (flat vs. avg buy price). Boundless Bio is a small-cap oncology biotech; Form 425 suggests a business combination in process. (filing 1) (filing 2)
  • FTH — CFO Brian C. Stephenson bought 13,634 shares ≈ $326K at $23.92 avg (June 29–July 1, filed July 6); now $24.49 (+2.4% since avg buy). CFO open-market buys in a small biotech are generally a high-conviction signal. (filing via Investing.com)

Watch: Fiserv (FISV) Cluster Buy + Catalyst

Not in the strict 24h window, but noteworthy: following CEO Mike Lyons' abrupt departure on June 15, 2026, four Fiserv insiders purchased a combined ~$1.07M in shares at $49.33–$50.59 (mid-June filings). FISV closed Monday July 6 at $51.78 and is indicated +7.5% premarket on July 7 following a Reuters report that Fiserv is exploring the sale of its STAR debit card network to major banks (JPMorgan, BofA, Wells Fargo). Insiders who bought at the dip are now up ~+9–12%.

Notes

  • Holiday compression: July 3 (observed) + July 4–5 weekend = no trading or filings. All significant purchase filings from the July 2 trading day landed on July 6.
  • Sector themes: Oncology biotech (NVCT + BOLD cluster) and refrigerant gas/environmental services (HDSN) dominate the buy list. The Tang Capital BOLD buys are particularly notable given the Form 425 suggesting a potential merger or strategic combination.
  • HDSN is the largest single name by dollar value; Hartree's continued accumulation (now ~11.8% stake) over multiple days signals a disciplined, thesis-driven position build rather than a one-off trade.
  • RH director buy at ~$161 suggests insider views on the luxury home goods cycle; stock has bounced to $169.

Most-bought stocks, last 30 days

  • HOOD $35.3M · 2 buysRobinhood Markets, Inc.
  • ARTV $16.6M · 3 buys, 3 insidersArtiva Biotherapeutics Inc.
  • NSP $15.9M · 2 buysInsperity Inc.
  • AVO $14.4M · 6 buys, 3 insidersMission Produce Inc
  • PBLS $10.2M · 2 buys, 2 insidersParabilis Medicines, Inc.
  • STEP $10.0M · 2 buysStepStone Group Inc.
  • PSEC $9.35M · 3 buys, 2 insidersProspect Capital Corp
  • TXO $8.23M · 1 buyTXO Partners, L.P.
  • HDSN $6.10M · 2 buys, 2 insidersHudson Technologies, Inc.
  • FUN $5.90M · 1 buySix Flags Entertainment Corporation
  • NVCT $4.66M · 8 buys, 2 insidersNuvectis Pharma, Inc.
  • SMMT $3.64M · 3 buys, 3 insidersSummit Therapeutics Inc.
  • COE $3.25M · 1 buy51Talk Online Education Group
  • FISV $3.25M · 7 buys, 4 insidersFiserv Inc.
  • LODE $2.89M · 2 buys, 2 insidersComstock Inc.
  • AII $2.30M · 1 buyAmerican Integrity Insurance Group, Inc.
  • WBX $2.25M · 2 buys, 2 insidersWallbox N.V.
  • FCNCA $2.04M · 2 buysFirst Citizens BancShares Inc.
  • AMR $2.01M · 1 buyAlpha Metallurgical Resources Inc.
  • GPGI $1.99M · 2 buysGPGI, Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.